Ipsen/Galderma's Azzalure approved for aesthetic use in Europe
This article was originally published in Scrip
Ipsen/Galderma's muscle relaxant for aesthetic use, Azzalure (botulinum type A toxin-haemagglutinin complex), has received marketing authorisations in15 European countries including the UK, Spain, and France for the treatment of glabellar lines.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.